Accueil   Diary - News   All news Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France



ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development



Vienna, Austria, and Illkirch (Strasbourg), France, May 11, 2020 – Themis, a clinical-stage biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, and ABL Europe (ABL), a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an agreement under which ABL will manufacture Themis’ vaccine candidate in preparation for clinical trials. The vaccine is being developed using a proprietary measles virus vaccine platform technology, which is licensed exclusively to Themis by the world-renowned Institut Pasteur in Paris.



Dr. Erich Tauber, CEO of Themis commented, “The key elements behind our decision to partner with ABL Europe are our past experience, their viral expertise and consequently the significant advantage of ABL being able to rapidly manufacture supplies to start our clinical trials.”



Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree